DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMeds AI (MEDS) announced that its wholly owned subsidiary Helomics entered a cancer drug discovery and development partnership with DiaGen AI. DataMeds will issue 630,000 common shares, equal to 9.9 percent of its common shares outstanding as of the agreement date. In return, it will receive 9.9 percent of DiaGen's fully diluted common shares outstanding. DataMeds expects the transaction to total $1.5 million in cash and in-kind contributions through research milestones and target validation.
The partners will initially test 15 peptides on primary breast tumor samples, including triple-negative breast cancer. The peptides have shown proof of concept in breast cancer cell lines, but how they work has not been established. Helomics and DiaGen will jointly own intellectual property from the target discovery work. DataMeds will cover up to 50 percent of computing expenses under the agreement.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointHelomics entered an agreement with DiaGen AI to identify breast cancer targets and evaluate drug candidates.
- Minor point. Forward-looking: it has not happened yet and may not happen.DataMeds will receive 9.9 percent of DiaGen's fully diluted common shares outstanding in the exchange.
- Minor point. Forward-looking: it has not happened yet and may not happen.Expected transaction value of $1.5 million includes cash and in-kind contributions through research milestones and target validation.
- Minor point. Forward-looking: it has not happened yet and may not happen.Helomics and DiaGen will jointly own intellectual property created by the target discovery work.
- Minor point15 peptides showed proof of concept in lab-grown breast cancer cells, including triple-negative breast cancer cells.
5 minor points
- Minor pointPublished lab testing found the peptides were at least 5.5-fold less toxic to normal human blood cells than to cancer cells.
- Minor point. Forward-looking: it has not happened yet and may not happen.DiaGen will cover direct lab experiment costs in cash as milestone benchmarks are achieved and funded.
- Minor point. Forward-looking: it has not happened yet and may not happen.Helomics will screen small-molecule candidates from DiaGen in cell lines and primary tumors, then work with DiaGen to confirm selections in breast cancer animal models.
- Minor point. Forward-looking: it has not happened yet and may not happen.Research milestones target a lead candidate with proof of concept in breast cancer animal models and in lab tests across up to thirteen cancer types.
- Minor point. Forward-looking: it has not happened yet and may not happen.Further development plans call for seeking pharmaceutical partners or launching a joint venture to fund the work.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.630,000 new common shares will dilute DataMeds holders; they equal 9.9 percent of common shares outstanding as of the agreement date.
- Minor point. Forward-looking: it has not happened yet and may not happen.DataMeds will cover up to 50 percent of computing expenses under the agreement, primarily from existing computing spending.
- Minor point. Forward-looking: it has not happened yet and may not happen.How the peptides work has not been established; testing in other cancer types depends on identifying their therapeutic targets.
News Explained
The partners will jointly work to identify the peptides’ mechanism; if they find a target, they will then assess whether it applies to other cancers in Helomics’ biobank, making the wider research scope contingent on target discovery.
Key Figures
- Peptides for initial validation
- 15
- Cytotoxic peptides with prior in vitro proof of concept in breast cancer cell lines
- Relative toxicity in published testing
- At least 5.5-fold less toxic
- Normal human blood cells compared with cancer cells
- DataMEDS shares issued
- 630,000 common shares
- Share exchange; equivalent to 9.9% of DataMEDS common shares outstanding as of the agreement date
- DiaGen shares issued
- 9.9%
- Of DiaGen's fully diluted common shares outstanding, issued to DataMEDS
- Compute expenses
- Up to 50%
- DataMEDS contribution toward compute expenses incurred under the agreement
- Expected transaction value
- $1.5 million
- Expected cash and in-kind contributions through completion of project milestones and target validations
- Cancer types for in vitro proof of concept
- Up to thirteen
- Stated milestone outcome for the therapeutic candidate
Key Terms
clia-certified regulatory
cytotoxic peptides medical
in vitro technical
mechanism of action medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL AND VANCOUVER, BC / ACCESS Newswire / November 18, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that its wholly-owned subsidiary Helomics, Inc. (Helomics), a CLIA-certified cancer diagnostics laboratory, has entered into a cancer target discovery and drug candidate optimization partnership with DiaGen.ai, an award-winning, AI-driven drug discovery company based in Vancouver, Canada.
Helomics maintains one of the world's largest repositories of primary tumor specimens (the "Helomics Biobank") with over 70,000 tumor biopsies, including more than 50,000 gynecologic cancer samples, amassed over nearly three decades. Helomics has also developed proprietary cell painting and patient-tumor derived 3D spheroids that represent a test matrix that preserves tumor stroma and correlates to its 2D platform with associated drug response data (commercially available, insurance reimbursed ChemoFx® Assay chemotherapy selection laboratory developed test), allowing for a unique high throughput testing approach. By introducing tumor heterogeneity at pre-clinical stages leveraging primary tumor features, Helomics hopes to inform better drug response predictions to enable the selection of drug/tumor combinations and increase the probability of clinical success.
The companies will initially focus on the validation of fifteen cytotoxic peptides identified using the methodology published in Nature Communications and implemented in DiaGen's CYPRESS platform that have already achieved in vitro proof of concept in breast cancer cell lines, including triple negative breast cancer cell lines (the "DiaGen Peptides"), and, in published testing, were at least 5.5-fold less toxic to normal human blood cells than to the cancer cells. The mechanism of action of the DiaGen Peptides has not yet been established. The companies will work jointly to elucidate the mechanism, test the peptides on primary tumors from the Helomics Biobank and protect the intellectual property created from the resulting discoveries. The DiaGen Peptides were identified based on the pioneering research of DiaGen Chief AI Officer Mohit Pandey, Ph.D., published in Nature Communications.
"Being able to access this robust primary tumor biobank and Helomics' proprietary capabilities to identify new therapeutic targets and leverage our proprietary BLACKCOMB artificial intelligence chemical drug discovery platform to design the best candidates for human clinical development is a transformative opportunity for DiaGen," said Dr. Mohit Pandey, Chief AI Officer (CAIO) of DiaGen.ai. "Building upon the foundational methodologies in my recent peer-reviewed research in Nature Communications, we know that the only way for artificial intelligence companies in the biotechnology space to truly differentiate themselves is to train their models on unique, high-dimensional biological data in areas of high unmet medical need. With this agreement, DiaGen is gaining access to an untapped resource of real-world tumor data upon which to build a novel intellectual property portfolio together with Helomics."
Under the terms of the agreement, DiaGen and Helomics will collaborate to perform therapeutic target discovery research and development activities to identify novel breast cancer therapeutic target(s) and evaluate the therapeutic potential of the DiaGen Peptides on primary breast cancer biopsies, including triple negative breast cancer. Upon discovery of the DiaGen Peptides' therapeutic target(s), the companies will work to identify whether this novel mechanism of action is applicable to other cancers in the Helomics Biobank, including GI cancer, brain cancer, head and neck cancer, genitourinary cancer, liver cancer, lung cancer, melanoma, mesothelioma, ovarian cancer, pancreatic cancer, sarcomas, and uterine cancer. Helomics and DiaGen will jointly own the intellectual property created from this target discovery exercise. DiaGen will create a library of drug candidates leveraging its BLACKCOMB artificial intelligence small molecule design platform. Helomics will perform pre-clinical in vitro cell line and primary tumor validation activities to identify the small molecules most suitable for therapeutic development and work together with DiaGen to confirm candidate selection in breast cancer animal models. The companies plan to work to partner the novel cancer drug target(s) and therapeutic candidate(s) with pharmaceutical partners or launch a joint venture to fund their further development.
As part of the agreement, the companies will consummate a share exchange in which DataMEDS will issue 630,000 common shares to DiaGen, (equivalent to 9.9 percent of DataMEDS common shares outstanding as of the date of the agreement) and DiaGen will issue 9.9 percent of its fully diluted common shares outstanding to DataMEDS in consideration. DataMEDS will contribute up to 50 percent of the compute expenses incurred under the agreement in furtherance of research milestones, sourced primarily from its existing compute spend. DiaGen will contribute the cash for the hard costs of the wet lab experiments conducted under the agreement per milestone benchmarks as they are achieved and funded. The total value associated with the transaction is expected to be
"We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab and will help us unlock the tremendous value resident in one of the world's largest curated biobanks while also allowing us to participate in the long-term value creation of biotechnology drug discovery," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "Helomics is also now open to establish new practicing oncologist relationships for its commercially available ChemoFx® Assay, as well as re-activate historical relationships, which will help us continue to grow the size and diversity of the Helomics Biobank. Partnering with DiaGen lets us contribute to the creation of groundbreaking new therapies that can improve the standard of care for patients with cancer while allowing us to participate in the value of the new intellectual property created leveraging our unique resources."
The global cancer therapeutics market is projected to grow from
For more information about DataMeds AI or Helomics, please contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.
About DiaGen AI Inc.:
Headquartered in Vancouver, DiaGen AI Inc. is developing a diverse pipeline of AI-powered tools for small molecule and peptide discovery, diagnostics, and delivery. Using its proprietary generative AI Blackcomb and Cypress Protocols, DiaGen aims to de-risk, accelerate, and create value across the global traditional SME drug discovery sector, advancing precision medicine and impacting global human longevity. DiaGen's research has been accepted at NeurIPS, the premier machine learning conference, and the company is a graduate of the Creative Destruction Lab at the University of Washington among other world-wide partnerships.
For more information, please reach out to us at IR@diagen.ai
Or, please visit www.diagen.ai
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
About Helomics Corporation
Helomics Corporation, a wholly owned subsidiary of DataMeds AI, Inc. (NASDAQ:MEDS), operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania, focused on precision oncology. Its flagship ChemoFx® Assay tests a patient's live tumor cells against a panel of chemotherapy agents to give oncologists patient-specific information to help inform treatment decisions in gynecologic cancers. ChemoFx is billed under CPT codes 81535 and 81536. Through Predictive Oncology, its Cancer Biomarker Super Intelligence (SI) division, Helomics combines a large annotated biobank of tumor samples, from over 130 tumor types, with artificial intelligence and multi-omic data. It uses these to help pharmaceutical and biotechnology partners predict tumor response and speed up oncology drug discovery and development. The ChemoFx Assay is a laboratory-developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit https://predictive-oncology.com/.
DataMEDS AI, Inc. Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: Helomics' ability to perform the research program with Diagen and to receive payments of up to
DiaGen AI, Inc. Forward-Looking Statement Cautions
This press release contains certain "forward-looking statements" within the meaning of Canadian securities legislation, relating to DiaGen AI, Inc.'s (the Company") plans and expectations. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates, " "believes," "intends, " "estimates," "projects," "aims," "suggests," "indicate," "often," "target," "future," "likely," "pending," "potential," "goal," "objective, " "prospective, " and "possibly," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. Forward-looking statements in this news release include statements relating to: the Company's ability to make advancements in industry using its proprietary technology; the Company's focus on the AI sector; the Company providing a return on investment for its shareholders; and the continued growth of the Company, viability of its technology; general applicability of AI technology towards the healthcare sector, particularly drug discovery, diagnostics, and vaccines; the ability of the Company to find strategic acquisitions and consummate transactions to acquire such entities; the ability of the Company to complete an intended go-public transaction; and the ability of the Company to use its technology to make a meaningful impact on the healthcare industry.
The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company's business and prospects.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to make advancements in industry using its proprietary technology; the Company's expectation of growth of the AI sector as it applies to healthcare; the Company's ability to provide a return on investment for its shareholders; the continued growth of the Company; the viability of the Company's technology; the continued applicability of AI technology within the healthcare sector, particularly drug discovery, diagnostics, and vaccines; the ability of the Company to find strategic acquisitions and consummate transactions to acquire such entities; the ability of the Company to successfully complete a go-public transaction in the near future; and the ability of the Company to use its technology to make a meaningful impact on the healthcare industry.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
DataMEDS AI Investor Contact
IR@datamedsai.com
###
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will DataMeds AI and DiaGen exchange under the Helomics partnership?
DataMeds will issue 630,000 common shares to DiaGen in exchange for 9.9 percent of DiaGen's fully diluted common shares outstanding. The shares DataMeds will issue equal 9.9 percent of its common shares outstanding as of the agreement date.
What has Helomics and DiaGen's initial group of cancer peptides shown so far?
The 15 peptides showed proof of concept in lab-grown breast cancer cells, including triple-negative breast cancer cells. In published testing, they were at least 5.5-fold less toxic to normal human blood cells than to the cancer cells. How the peptides work has not yet been established.
How will DataMeds AI and DiaGen pay for the Helomics research?
DataMeds will contribute up to 50 percent of computing expenses under the agreement, primarily from existing computing spending. DiaGen will pay cash for direct lab experiment costs as milestone benchmarks are achieved and funded.
When will Helomics and DiaGen look at cancers beyond breast cancer?
Helomics and DiaGen will assess whether the peptides' mechanism of action, or how they work, applies to other cancers after identifying the peptides' therapeutic targets. The planned work would use samples from the Helomics Biobank, including ovarian, lung and pancreatic cancers.